OMEGA Diagnostics has seen its shares fall almost 18 per cent after warning it could not accurately forecast how much of its highly anticipated HIV testing kit will be sold this year.
The company confirmed field evaluations of the Visitect CD4 system, manufactured at its headquarters in Alva, Clackmannanshire, in Kenya and India have seen 340 patients tested so far.
However, Omega admitted it is difficult to predict when non-government organisations (NGOs) are likely to want to buy it in large quantities.
House broker FinnCap reduced its expectation for CD4 sales in the 2015 financial year from £5 million to £1.5 million but included the higher sum in a forecast for the following 12 months.
David Evans, Omega chairman, said: "CD4 will, without doubt, be a successful product for the Group, but we would be foolish to believe that our crystal ball is better than yours in being able to forecast with certainty the decision outputs from the NGOs we are working with.
"This is primarily a global tender-based business, with timing driven by the availability of funds and the view of the various governments as to need at that time."
That came as the company, which employs 43 of its 145 staff in Scotland, recorded a three per cent rise in annual turnover from £11.3 million to £11. 6 million.
Pre-tax profits almost doubled from £276,224 to £543,041 in the 12 months to March 31 this year.
Following the trend of recent years the food intolerance division was the star performer with an 18 per cent rise in sales from £4.39 million to £5.18 million with strong sales reported in France, Spain, Brazil and Poland.
The company said it expects double digit percentage growth in this area and is targeting markets such as Mexico, Canada and India.
The allergy and autoimmune segment, mainly based in Germany, fell from £4.16 million to £3.97 million as a result of strict doctor purchasing restrictions operating in its main market.
The infectious diseases arm saw a drop in revenue from £2.71 million to £2.45 million which was attributed to one UK customer which had experienced financial difficulties and reduced its custom.
Omega also outlined a potential pipeline of new product areas including a point-of-care test for syphilis which it has licensed technology from the Burnet Institute in Australia, which was also the originator of the CD4 technology.
Andrew Shepherd, chief executive, said: "It is a test that has great potential from what we are hearing from the global health market."
Trials for a test for schistosomiasis, a disease caused by a worm present in many tropical countries and which it is estimated 200 million people are infected with, could start in the second half of this financial year.
Mr Shepherd said: "Omega is working with an expert in this disease area and good early progress is being made in the development of a new lateral flow test."
Further down the line Omega is also looking into the possibilities for a simple test to determine the amount of the HIV virus in body fluids.
A smartphone app which scans the results of the CD4 tests and uploads them to a central server is also being rolled out and will be customisable for other disease tests.
Shares closed down 5p at 23.25p.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article